Multiple myeloma (MM) is a B-cell malignant neoplasm characterized by clonal expansion of terminally differentiated B cells (plasma cells) in the bone marrow, associated with the synthesis of a monoclonal immunoglobulin and a high incidence of osteolytic bone lesions. MM is called plasma cell leukemia (PCL) when the absolute plasma cell count is more than 2 × 10 9 /L or when plasma cells represent more than 20% of peripheral blood cells. 1 In monoclonal gammopathies of uncertain significance (MGUS), a monoclonal protein is present in the serum without evidence of any causal disease, and there is low plasma cell count in the bone marrow. 2 MM is one of the frequent hematologic disorders and represents about 10% of all hematologic malignant neoplasms. 3 In lymphoproliferative disorders of the bone marrow, MM represents 42% of B-cell tumors and affects mainly older patients in their sixth or seventh decades of life. 4 The clinical course of MM is very different, and survival time ranges between a few months and several years related to plasma cell mass and stage of disease. 5 Cytogenetic analysis is an important part of myeloma diagnosis because monosomy 13 or deletions in the long arm of chromosome 13 have been identified to be prognostic factors. 6 Information based on conventional karyotyping is limited because malignant plasma cells have low spontaneous proliferative activity. 7 By conventional G-banding, chromosomal aberrations are described in about 20% to 50% of the cases. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The karyotypes of MM usually are greatly complex and more similar to those of epithelial tumors than other hematopoietic disorders.
A number of genetic abnormalities have been detected in multiple myeloma (MM) using cytogenetic techniques. The prominent abnormalities are deletions of 13q and translocations affecting the IgH locus on 14q32. The recurrence of chromosomal abnormalities in MM suggests a specific role for them concerning its pathogenesis. We performed comparative genomic hybridization (CGH) on samples from 53 patients with MM and 4 with monoclonal gammopathies of undetermined significance. In 31 cases (54%), normal ratio profiles were found, whereas 26 cases (46%) had aberrant profiles. The most common aberrations were gains of 9p (n = 14), 11 (n = 9), and 21q (n = 5) and loss of 22 (n = 7). In earlier reports on cytogenetics of lymphomas, gains of 9p are described as characteristic of primary mediastinal B-cell lymphoma, but the consensus region is smaller than in the present study (9p23pter vs 9p13pter). Therefore, we suggest a stronger genetic affinity between MM and primary mediastinal B-cell lymphoma than between MM and other B-cell lymphomas. To support this suggestion, more molecular cytogenetic techniques and expression analyses have to be performed.
Multiple myeloma (MM) is a B-cell malignant neoplasm characterized by clonal expansion of terminally differentiated B cells (plasma cells) in the bone marrow, associated with the synthesis of a monoclonal immunoglobulin and a high incidence of osteolytic bone lesions. MM is called plasma cell leukemia (PCL) when the absolute plasma cell count is more than 2 × 10 9 /L or when plasma cells represent more than 20% of peripheral blood cells. 1 In monoclonal gammopathies of uncertain significance (MGUS), a monoclonal protein is present in the serum without evidence of any causal disease, and there is low plasma cell count in the bone marrow. 2 MM is one of the frequent hematologic disorders and represents about 10% of all hematologic malignant neoplasms. 3 In lymphoproliferative disorders of the bone marrow, MM represents 42% of B-cell tumors and affects mainly older patients in their sixth or seventh decades of life. 4 The clinical course of MM is very different, and survival time ranges between a few months and several years related to plasma cell mass and stage of disease. 5 Cytogenetic analysis is an important part of myeloma diagnosis because monosomy 13 or deletions in the long arm of chromosome 13 have been identified to be prognostic factors. 6 Information based on conventional karyotyping is limited because malignant plasma cells have low spontaneous proliferative activity. 7 By conventional G-banding, chromosomal aberrations are described in about 20% to 50% of the cases. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The karyotypes of MM usually are greatly complex and more similar to those of epithelial tumors than other hematopoietic disorders.
Comparative genomic hybridization (CGH) is a powerful supplement in the cytogenetic characterization of MM owing to its ability to detect genetic imbalances without tumor metaphases.
The application of molecular cytogenetic methods such as CGH or fluorescence in situ hybridization (FISH) increases the percentage of chromosomal aberrations detected in MM. 20 Chromosomal aberrations detected by CGH are known only in a limited number of cases. Five studies on series of 8 to 46 patients with MM, PCL, MGUS, and myeloma cell lines have shown gains and losses in different chromosomal regions and with varying frequency. [21] [22] [23] [24] [25] The results are controversial, and most of the data have not been validated using FISH. The first study 21 describes gains of chromosomes 7 and 8 in 25% of the cases and gains in the long arm of chromosomes 1, 2, 9, and 8 in 63%. Losses were seen in the long arm of chromosome 13 in 63% of the cases and in the long arm of chromosome 14 in 38%. CGH in the second study 22 showed gains of 19 and 19p in 30%, 11q in 20%, and 17q in 13% and losses of 13 and 13q in 30%, 16 and 16q in 17%, and 6q in 13%. The most frequent chromosomal imbalances detected in the third study 23 were gains of 1q (58%), 9q (58%), 19p (58%), 7p (42%), 11q (38%), 15 (33%), 6p (25%), 8q (25%), and 5p (21%) and losses of 13q (79%), 1p (42%), 14q (33%), X (33%), 8p (25%), 6q (25%), and 4 (21%). The fourth study 24 described differences in chromosomal abnormalities between MM and PCL. It showed gains of 15q (48%), 11q (44%), 3q (40%), 9q (40%), and 1q (36%) and losses of 13q (80% PCL vs 28% MM), chromosome 16 (80% PCL vs 16% MM), and 2q and 6p only in patients with PCL. The latest study 25 with the highest number of patients (n = 46) detected frequent chromosomal gains of 1q (26%), 9q (15%), 11q (15%), 9p (11%), 5p (11%), 5q (11%), 6p (11%), 15 (11%), and 18q (11%) and losses of 13q (37%), 6q (15%), 8p (15%), Xp (15%), Xq (15%), and 1p (13%).
We performed CGH in the largest series to date-57 patients with plasma cell neoplasms. The results were validated by FISH, compared with conventional cytogenetics, and correlated with clinical data. The aim of our study was to identify possible chromosomal imbalance patterns and regions that could have a role in the pathogenesis of MM.
Materials and Methods

Cases
For the present study, we used bone marrow samples sent for cytogenetic analysis to the Department of Human Genetics, University Hospital, Münster, Germany. We selected 57 samples on the basis of suitable material being available from diagnostic samples for CGH and FISH analyses. The tumors were staged using the clinical system of Durie and Salmon. 26 Clinical and laboratory data for the patients are given in ❚Table 1❚.
Cytogenetic Analysis
Bone marrow aspirates were obtained as heparinized samples. Leukocytes were isolated by density centrifugation as previously described. 27 Samples were cultured for up to 72 hours and then exposed to colcemid (Gibco, Karlsruhe, Germany) 30 minutes before harvest. After hypotonic treatment and fixation, GTG banding was used for karyotype analysis. Approximately 20 metaphases were analyzed. The karyotypes were reported according to the International System of Cytogenetic Nomenclature. 28 
Metaphase Spreads for CGH
Metaphase spreads needed for CGH were prepared from phytohemagglutinin-stimulated lymphocytes of a healthy male donor as described earlier. 27 Up to 200 slides were prepared at once and used for this study only after CGH with differentially labeled reference DNA had been performed as quality control.
DNA Isolation and Labeling
High-molecular-weight genomic DNA was isolated by a standard phenol-chloroform extraction procedure after Proteinase K digestion. 29 Reference DNA was obtained from blood samples of healthy male and female donors. Tumor DNA was isolated from methanol/acetic acid-fixed cells stored at -80°C after G-banding analysis was closed. We labeled 1 µg of each tumor and reference DNA by nick translation using a kit according to the manufacturer's instructions (Vysis, Bergisch Gladbach, Germany). Tumor DNA was 
8.00-12.80 (9.60) 
labeled with SpectrumGreen-conjugated deoxyuridine triphosphate and reference DNA with SpectrumRed-conjugated deoxyuridine triphosphate (Vysis). The size of the labeled DNA was verified on a 2% agarose gel to be in the range of 300 to 1,000 base pairs.
Hybridization and Detection
For hybridization and detection, 400 ng of each, labeled tumor and reference DNA, and an excess of human cot1 DNA (20 µg) were precipitated with ethanol, air dried, and dissolved in 10.5 µL of hybridization buffer (20% dextran sulfate, 4× standard saline citrate [SSC], 50% deionized formamide). This mixture was denatured at 72°C for 5 minutes. Normal metaphase spreads were denatured in 70% formamide/2× SSC (pH 7.0) at 72°C ± 2°C for 3.5 minutes, dehydrated in a series of ice-cold ethanol (70%, 80%, and 100%) for 2 minutes each, and dried at 60°C. The denatured CGH probe was pipetted directly onto the slides, closed with a coverslip, and sealed with rubber cement. Hybridization was performed in a humidified dark chamber at 37°C for 3 days.
Slides were washed in 0.4× SSC/0.3% Nonidet P-40 (Roche, Karlsruhe, Germany) at 72°C ± 2°C for 2 minutes followed by 2× SSC/0.1% Nonidet P-40 at room temperature for 1 minute. Slides were allowed to air dry in the dark for 20 minutes. We used 10 µL of 4,6-diamino-2-phenylindole (DAPI, 40 ng/mL) containing p-phenylenediamine dihydrochloride (1 mg/mL) as the counterstain.
Image Acquisition and Analysis
Metaphases were acquired under ×100 magnification using an epifluorescence microscope (Zeiss Axioplan 2, Carl Zeiss Göttingen, Göttingen, Germany) equipped with a 100-W mercury lamp; filter sets for an excitation of 365, 450 to 490, and 546 nm; and a cooled charge-coupled device camera (JAM M300, JAI, Yokohama, Japan). Image analysis was performed with the Isis software (MetaSystems, Althusheim, Germany). Mean ratio profiles of SpectrumGreen to SpectrumRed were calculated for 10 metaphases. Diagnostic thresholds used to define losses and gains were set at 0.85 and 1.17. 30
Interphase FISH
FISH was used to validate the CGH results. FISH using commercially available probes was performed according to the manufacturer's protocols. All commercially available FISH probes were obtained from Vysis. In addition, we used locus-specific probes generated from DNA of yeast artificial chromosome, P1-derived artificial chromosome (PAC), and bacterial artificial chromosome provided by Centre d'Etude du Polymorphisme Humain (Paris, France) and the University of Bari (Bari, Italy). Generation of probes was performed as previously described. 31 PAC DNA was isolated using the QIAgen Large-Construct-Kit (Qiagen, Hilden, Germany).
Cells fixed on slides were denatured in 70% formamide/2× SSC at 70°C for 2 minutes and hybridized overnight in a humidified chamber at 37°C. Posthybridization washes were done in 0.1× SSC at 60°C 3 times. Detection was achieved with a fluorescein-labeled antibiotin antibody system (Oncor, Heidelberg, Germany). Nuclei were counterstained with DAPI/antifade (Oncor).
Analyses were performed with an epifluorescence microscope as described for CGH. At least 250 nuclei were counted. Thresholds for aberrant counts were defined for each probe by evaluation of signal distribution in 10 normal samples.
Results
Conventional Cytogenetics
We studied 57 cases by conventional cytogenetics. G-banding analysis was successful in 53 cases (93% 
Comparative Genomic Hybridization
CGH was successful in all 57 cases. Only losses or gains validated by FISH were classified as aberrations. Chromosome Y was not included in the classification owing to its generally poor hybridization caused by insufficient suppression by cot1 DNA. The others were assumed to be artifacts of CGH. Of 57 cases, 31 (54%) showed normal ratio profiles, and 26 (46%) were aberrant. Whole chromosome gains concerned chromosomes 11 (n = 9); 3, 5, 7, 8, 9, and 15 (n = 3 each); 21 (n = 2); and 16 (n = 1). Monosomies were found for chromosomes 22 (n = 7); 19 (n = 2); and 13, 16, and 17 (n = 1 each). Frequently deleted chromosomal regions were 12q (n = 3) and 1p, 9q, 16q, and 21q (n = 2 each). Gains were frequent on regions 9p (n = 11); 21q (n = 3); and 5p and 11q (n = 2 each). The distribution of gains and losses among all chromosomes is traced in ❚Figure 1❚.
Correlation of CGH Results With Conventional Cytogenetics
Nineteen cases with normal karyotype using G-banding showed aberrant ratio profiles ❚Table 4❚. All 4 cases lacking metaphases for conventional cytogenetics were aberrant using CGH ❚Table 5❚. For cases in which both methods detected anomalies, the failure of CGH to detect nullisomy Y was not considered a discrepancy in the techniques. In 2 cases (1215 and 1848), all changes detected by CGH have already been described after G-banding, but conventional cytogenetics showed additional aberrations. In case 1215 derivative chromosomes 1, 8, 16, and 17 probably are balanced aberrations because they did not result in gains or losses. Trisomy 9 and der(13) result in a gain of 9p. In addition to other changes, trisomy 15 was found in only 1 metaphase of 20 by conventional cytogenetics. This could explain the lack of detection by CGH. In case 1848, monosomy 16, trisomy 19, and a marker chromosome were missed using CGH. In case 1422, the clone found using conventional cytogenetics was absolutely different from the one detected by CGH. Karyotypes and CGH profiles are detailed in Table 3 .
Discussion
Chromosomal aberrations such as monosomy 13, deletion of 13q, and IgH (14q32.3) rearrangements have a role as prognostic factors in the management of MM. In the present study, a molecular cytogenetic technique, CGH, was applied in addition to conventional cytogenetics for the analysis of cases of MM or MGUS. CGH results were validated with appropriate FISH probes. Of 57 cases, 28 (49%) showed abnormalities with at least one of these techniques. The 5 previous reports of CGH on MM had a range of 63% to 100%. [21] [22] [23] [24] [25] The low percentage in our study can be explained by the inclusion of more patients with normal karyotypes using G-banding than in the other studies (91% [48/51] vs ~40%) and by the low quantity of bone marrow plasma cells (BMPCs), ranging from 3% to 95%. We nevertheless included patients with BMPCs lower than 50% because the BMPC values have some variation depending on the anatomic location of the bone marrow aspiration and the analyst. BMPC, bone marrow plasma cell index; CC, conventional cytogenetics; CGH, comparative genomic hybridization; D, at diagnosis; MM, multiple myeloma; T, under or after therapy. * Differences between techniques are given in bold.
In the 5 cases with aberrations shown by conventional cytogenetics, a high level of concordance was noted between CGH profiles and G-banded karyotypes. All 4 cases without G-banded karyotypes showed chromosomal changes with CGH. CGH showed gains and/or losses in 19 (40%) of 48 cases with normal karyotypes after G-banding. Chromosomal gains were far more frequent than losses, mostly involving 9 or 9p (14/57 [25%]), 11 (8/ [4%] ). These data are only partially in accordance with previous data. With the exception that percentages of detected changes are higher in the other studies, this is the only study describing gains of 9p. Liebisch et al 25 described gains of 9p, but these were always within gains of the whole chromosome 9. In agreement with Liebisch et al, 25 who described gains of chromosome 11 in addition to gains of 11q, CGH detected gains of the whole chromosome 11 in the present study. The other 4 studies describe gains of only 11q as a frequent event. Gains of 21q are described only by Avet-Loiseau et al 21 and solely in cell lines. Losses of 22 are mentioned only by Aalto et al. 23 CGH detected losses of 13 or 13q in 2 (4%) of 57 cases, in contrast with FISH, in which deletion of 13q14.3 (locus D13S319) was found in 10 (18%) of 55 cases. This might be due to the low number of cells carrying the deletion or to the small size of this deletion.
To our knowledge, this is the first study that describes gains of 9p in MM in addition to formerly described changes such as gains of chromosome 11 and 21 and loss of chromosome 22. Gains of chromosome region 9p or whole chromosome 9 were detected only in stage III (A and B) MM and in a case of MM combined with an acute leukemia. Because of its relative high frequency (14/57 [25%] in this study), gains of 9p might have an important role in the biology of this disease. In a comparison between primary mediastinal B-cell lymphoma (PMBL) and other B-cell lymphomas but not MM, Bentz et al 32 found gains of 9p to be highly characteristic of PMBL. In an earlier study, Joos et al 33 described gains of 9p to be characteristic of PMBL, which is classified as a mature B-cell neoplasm, such as MM and most of the B-cell lymphomas. The consensus region in both studies was assigned to be further telomeric to bands 9p23 and 9p24. In the present study, the consensus region was greater: 9p13pter. In addition to JAK2 and NFIB suggested by Bentz et al, 32 we propose CDKN2A (INK4A, p16), CDKN2B (INK4B, p15) , and PAX5 as further candidate genes on 9p. CDKN2A and CDKN2B, some of the most frequently disrupted tumor suppressor loci in human cancer, are located on chromosome 9 in region p21. They encode 2 inhibitors of cyclin-dependent kinases (CDK4 and CDK6) and upstream regulators of Rb function, p16 and p15, each of which is capable of inducing cell cycle arrest at the G 1 phase. Alterations of p16 and p15 occur at high incidence in MM solely by hypermethylation of 5' CpG islands and not by homozygous deletions or mutations as described for other tumors. 34 The functions of p16 and p15, therefore, are hampered by this hypermethylation, thus allowing clonal plasma cells to enter the S phase. Trisomy 9 provides a normal extra copy of p16 and p15 that increases the probability of a nonhypermethylated gene copy continuing to work normally despite the hypermethylation. Pérez-Simón et al 35 describe better overall survival for patients with trisomy 9 (46 vs 26 months) and trisomy 17 (103 vs 33 months). The duration of the present study was not long enough to correlate the results of the CGH with variables such as overall survival.
The human PAX5 (paired box gene 5) is located in chromosomal region 9p13. It encodes the transcription factor Bcell lineage-specific activator protein, which is essential for the generation and maintenance of B lineage-committed cells. PAX5 may be crucial in the control of proliferation of mature B cells, and its deregulated expression might contribute to abnormal proliferation and, thus, to lymphomagenesis. 36 A chromosomal translocation, t(9;14)(p13;q32), involving PAX5 and the potent Eµ enhancer of the IgH gene resulting in overexpression of PAX5 in B cells is reported in cases of B-cell lymphoma. 37 Gains of 9p increase the copy number of PAX5 and, consequently, also might result in its overexpression.
With reference to prognostic factors, hypodiploidy is associated with a poor prognosis, whereas hyperdiploid variants are associated with longer survival in MM and MGUS. [17] [18] [19] 35, [38] [39] [40] [41] In our study, 11 (19%) of 57 cases were hyperdiploid using CGH, with 4 cases showing trisomy 9 among other changes. According to the aforementioned FISH study by Pérez-Simón and colleagues, 35 trisomies of chromosomes 6, 9, and 17 are good prognostic factors with longer overall survival rates than trisomies of other chromosomes and no trisomy at all.
Another parameter, β 2 -microglobulin (β 2 -M), is supposed to be an independent prognostic factor associated with poor prognosis if the level is increased. 42 The present study seems to confirm this finding because 12 (75%) of 16 patients with aberrations had an increased level of β 2 -M (>170 nmol/L). Only 3 (20%) of 15 patients with either normal karyotypes or normal ratio profiles had an increased level of β 2 -M. The mean β 2 -M level for patients with either normal karyotypes or normal ratio profiles was 2.3 (range, 0.7-8.1). For patients with either aberrant karyotypes or aberrant ratio profiles, the mean was 4.7 (range, 1.7-13.0). In comparison with β 2 -M, the quantity of BMPCs seems to correlate less with the karyotype. Of 25 patients with aberrations, 11 (44%) had a BMPC quantity higher than 50% compared with 7 (27%) of 26 patients with either normal karyotypes or normal ratio profiles. With reference to the β 2 -M level and BMPCs, there was no difference between patients with and without gains of 9 or 9p, 11, and 21 or 21q or losses of 22. The generalization of these results is limited by the small numbers of patients for each category.
This report shows the need to supplement conventional cytogenetics with molecular cytogenetic techniques such as FISH and CGH. In addition, our findings show that all cases have to be analyzed, even though the BMPC quantity is very low. To the best of our knowledge, this is the first report on gains of 9p in MM. The chromosomal region 9p includes a large number of candidate genes. To characterize all these genes and understand the biologic and clinical significance of gains or amplifications of 9p, further molecular and molecular cytogenetic studies and gene expression analyses have to be done.
